id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-2028-0005,FDA,FDA-2022-E-2028,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2023-12-04T05:00:00Z,2023,12,2023-12-04T05:00:00Z,,2023-12-04T16:59:41Z,,0,0,09000064862d463f
FDA-2022-E-2028-0004,FDA,FDA-2022-E-2028,Determination of Regulatory Review Period for Purposes of Patent Extension; Qelbree,Notice,Determinations,2023-11-30T05:00:00Z,2023,11,2023-11-30T05:00:00Z,2024-05-29T03:59:59Z,2023-11-30T17:07:32Z,2023-26301,0,0,09000064862c32de